David A. Siegel Harvard Bioscience Inc Transaction History

Two Sigma Advisers, LP

$47 Billion
Q3 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Harvard Bioscience Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 243,156 shares of HBIO stock, worth $158,051. This represents 0.0% of its overall portfolio holdings.

Number of Shares

243,156

Previous 46,851 419.0%

Holding current value

$158,051

Previous $20,000 420.0%

% of portfolio

0.0%

Previous 0.0%

33 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$0.4 - $0.57 $78,522 - $111,893	196,305 Added 419.0%	243,156 $104,000
Q2 2025 Aug 14, 2025	SELL	$0.28 - $0.69 $24,837 - $61,206	-88,705 Reduced 65.44%	46,851 $20,000
Q1 2025 May 15, 2025	BUY	$0.57 - $2.19 $60,989 - $234,330	107,000 Added 374.7%	135,556 $77,000
Q4 2024 Feb 14, 2025	SELL	$2.02 - $2.82 $23,028 - $32,147	-11,400 Reduced 28.53%	28,556 $60,000
Q3 2024 Nov 14, 2024	SELL	$2.64 - $3.54 $94,248 - $126,378	-35,700 Reduced 47.19%	39,956 $107,000

Q2 2024 Aug 14, 2024	SELL	$2.77 - $4.63 $34,625 - $57,875	-12,500 Reduced 14.18%	75,656 $215,000
Q1 2024 May 15, 2024	SELL	$4.02 - $5.39 $68,741 - $92,169	-17,100 Reduced 16.25%	88,156 $373,000
Q4 2023 Feb 14, 2024	SELL	$4.0 - $5.49 $319,200 - $438,102	-79,800 Reduced 43.12%	105,256 $563,000
Q3 2023 Nov 14, 2023	BUY	$4.0 - $5.82 $240,800 - $350,364	60,200 Added 48.22%	185,056 $795,000
Q2 2023 Aug 14, 2023	BUY	$4.19 - $6.16 $139,527 - $205,128	33,300 Added 36.37%	124,856 $685,000
Q1 2023 May 15, 2023	SELL	$2.45 - $4.22 $149,940 - $258,263	-61,200 Reduced 40.06%	91,556 $384,000
Q4 2022 Feb 14, 2023	SELL	$2.12 - $2.86 $128,226 - $172,984	-60,484 Reduced 28.36%	152,756 $423,000
Q3 2022 Nov 14, 2022	BUY	$2.33 - $3.92 $131,840 - $221,809	56,584 Added 36.12%	213,240 $546,000
Q2 2022 Aug 15, 2022	SELL	$3.28 - $6.42 $33,784 - $66,126	-10,300 Reduced 6.17%	156,656 $564,000
Q1 2022 May 16, 2022	SELL	$5.16 - $7.14 $434,472 - $601,188	-84,200 Reduced 33.52%	166,956 $1.04 Million
Q4 2021 Feb 14, 2022	SELL	$6.37 - $8.18 $310,856 - $399,184	-48,800 Reduced 16.27%	251,156 $1.77 Million
Q3 2021 Nov 15, 2021	SELL	$6.98 - $8.47 $16,054 - $19,481	-2,300 Reduced 0.76%	299,956 $2.09 Million
Q2 2021 Aug 16, 2021	BUY	$5.44 - $8.4 $727,328 - $1.12 Million	133,700 Added 79.32%	302,256 $2.52 Million
Q1 2021 May 17, 2021	BUY	$3.91 - $6.99 $107,525 - $192,225	27,500 Added 19.5%	168,556 $920,000
Q4 2020 Feb 16, 2021	BUY	$3.0 - $4.5 $154,200 - $231,300	51,400 Added 57.33%	141,056 $605,000
Q3 2020 Nov 16, 2020	BUY	$2.75 - $4.2 $5,775 - $8,820	2,100 Added 2.4%	89,656 $270,000
Q2 2020 Aug 14, 2020	SELL	$2.12 - $3.14 $3,816 - $5,652	-1,800 Reduced 2.01%	87,556 $271,000
Q1 2020 May 15, 2020	SELL	$1.42 - $3.29 $18,744 - $43,428	-13,200 Reduced 12.87%	89,356 $197,000
Q4 2019 Feb 14, 2020	SELL	$2.45 - $3.25 $76,685 - $101,725	-31,300 Reduced 23.38%	102,556 $313,000
Q3 2019 Nov 14, 2019	BUY	$1.59 - $3.47 $105,258 - $229,714	66,200 Added 97.85%	133,856 $412,000
Q2 2019 Aug 14, 2019	BUY	$1.93 - $4.59 $85,692 - $203,796	44,400 Added 190.92%	67,656 $135,000
Q1 2019 May 15, 2019	SELL	$2.77 - $4.38 $554 - $876	-200 Reduced 0.85%	23,256 $100,000
Q4 2018 Feb 14, 2019	SELL	$3.03 - $5.0 $7,271 - $12,000	-2,400 Reduced 9.28%	23,456 $75,000
Q3 2018 Nov 14, 2018	BUY	$5.0 - $6.65 $13,060 - $17,369	2,612 Added 11.24%	25,856 $136,000
Q2 2018 Aug 14, 2018	SELL	$4.2 - $5.95 $3,830 - $5,426	-912 Reduced 3.78%	23,244 $124,000
Q1 2018 May 15, 2018	SELL	$3.3 - $5.15 $660 - $1,030	-200 Reduced 0.82%	24,156 $121,000
Q4 2017 Feb 14, 2018	SELL	$3.08 - $3.8 $616 - $760	-200 Reduced 0.81%	24,356 $80,000
Q3 2017 Nov 14, 2017	BUY	$2.7 - $3.75 $66,301 - $92,085	24,556	24,556 $92,000

Others Institutions Holding HBIO

# of Institutions

Shares Held

19.5M

Call Options Held

54K

Put Options Held

View Full List

About HARVARD BIOSCIENCE INC

Ticker HBIO
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 41,636,500
Market Cap $27.1M
Description
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as w...

More about HBIO

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account